NextCell Pharma

What was initially intended as a one-year interim solution developed into four years of close collaboration, during which Patrik played a central role in building NextCell Pharma AB into a group comprising the subsidiaries Cellaviva and QVance.

"We would like to extend our sincere thanks to Patrik for his dedication and valuable contributions over the years. His efforts have been both more extensive and longer-lasting than originally planned, and we wish him every success in his future career," says Mathias Svahn, CEO of NextCell Pharma.